Journal ArticleDOI
Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.
Javier Cortes,Geraldine Gebhart,Manuel Ruiz Borrego,Agostina Stradella,Begoña Bermejo,Santiago Escrivá,Lourdes Calvo Martínez,Nuria Ribelles,Noelia Martínez,Cinta Albacar,Aleix Prat,Florence Dalenc,Kerrou Khaldoun,Peter Schmid,Marco Colleoni,Frederik Marmé,Noemia Afonso,Miguel Sampayo-Cordero,Jose Perez-Garcia,Antonio Llombart-Cussac +19 more
TLDR
Dual trastuzumAB plus pertuzumab plusHP has shown promising pathologic complete response (pCR) rates in HER2[+] EBC although lower to CT regimens.Abstract:
503Background: Dual trastuzumab plus pertuzumab (HP) has shown promising pathologic complete response (pCR) rates in HER2[+] EBC although lower to CT regimens. Identification of new markers of sens...read more
Citations
More filters
Journal ArticleDOI
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
Anna van der Voort,Mette S. van Ramshorst,Mette S. van Ramshorst,Erik van Werkhoven,I.A.M. Mandjes,Inge Kemper,Annelie J. Vulink,Irma M. Oving,Aafke H. Honkoop,Lidwine W. Tick,Agnes J. van de Wouw,Caroline M.P.W. Mandigers,Laurence J. C. van Warmerdam,Jelle Wesseling,Marie-Jeanne T. F. D. Vrancken Peeters,Sabine C. Linn,GS Sonke,GS Sonke +17 more
TL;DR: The TRAIN-2 trial as mentioned in this paper evaluated 3-year event-free survival (EFS) and overall survival (OS) of an anthracycline-free and Anthracyline-containing regimen with dualERBB2blockade in patients with stage II and IIIERBB 2-positive breast cancer.
Journal ArticleDOI
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response
Katherine McNamara,Jennifer L. Caswell-Jin,Rohan P. Joshi,Zhicheng Ma,Eran Kotler,Gregory R. Bean,Michelle Kriner,Zoey Zhou,Margaret L. Hoang,Joseph M. Beechem,Jason J. Zoeller,Michael F. Press,Dennis J. Slamon,Sara A. Hurvitz,Christina Curtis +14 more
TL;DR: It is demonstrated that proteomic changes after a single cycle of HER2-targeted therapy aids the identification of tumors that ultimately undergo pCR, outperforming pre-treatment measures or transcriptomic changes.
Posted ContentDOI
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response
Katherine McNamara,Jennifer L. Caswell-Jin,Rohan P. Joshi,Zhicheng Ma,Eran Kotler,Gregory R. Bean,Michelle Kriner,Zoey Zhou,Margaret L. Hoang,Joseph M. Beechem,Dennis J. Slamon,Sara A. Hurvitz,Christina Curtis +12 more
TL;DR: Robust stratification of sensitive tumors early during neoadjuvant HER2-targeted therapy using a multiplex spatial proteomic biomarker with implications for tailoring subsequent therapy is demonstrated.
Journal ArticleDOI
Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Sonia Pernas,Sara M. Tolaney +1 more
TL;DR: The use of trastuzumab to chemotherapy dramatically improved the prognosis of early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer as discussed by the authors.
Journal ArticleDOI
Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer.
TL;DR: In this article, the role of the neoadjuvant setting as a research platform to facilitate and rationalize the placement of escalation strategies, promote the adoption of biomarker-driven approaches for the investigation of de-escalated treatments, and foster the conduction of comprehensive translational analyses, thus ultimately aiming at pursuing treatment personalization.
Related Papers (5)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,L Roman,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham Ross,Pinuccia Valagussa +19 more
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz,Chiun Sheng Huang,Max S. Mano,Sibylle Loibl,Eleftherios P. Mamounas,Michael Untch,Norman Wolmark,P Rastogi,Andreas Schneeweiss,Andrés Redondo,Hans Holger Fischer,William Jacot,Alison Conlin,Claudia Arce-Salinas,Irene Wapnir,Christian Jackisch,Michael P. DiGiovanna,Peter A. Fasching,John Crown,Pia Wülfing,Zhimin Shao,Elena Rota Caremoli,Haiyan Wu,Lisa H. Lam,David Tesarowski,Melanie C. Smitt,Hannah Douthwaite,Stina M. Singel,Charles E. Geyer +28 more
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar,Lijun Zhang,Michael Untch,Keyur Mehta,Joseph P. Costantino,Norman Wolmark,Hervé Bonnefoi,David Cameron,Luca Gianni,Pinuccia Valagussa,Sandra M. Swain,Tatiana M. Prowell,Sibylle Loibl,D. Lawrence Wickerham,Jan Bogaerts,José Baselga,Charles M. Perou,Gideon M. Blumenthal,Jens Uwe Blohmer,Eleftherios P. Mamounas,Jonas Bergh,Vladimir Semiglazov,Robert Justice,Holger Eidtmann,Soonmyung Paik,Martine Piccart,Rajeshwari Sridhara,Peter A. Fasching,Leen Slaets,Shenghui Tang,Bernd Gerber,Charles E. Geyer,Richard Pazdur,Nina Ditsch,Priya Rastogi,Wolfgang Eiermann,Gunter von Minckwitz +36 more
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis J. Slamon,Wolfgang Eiermann,Nicholas J. Robert,Tadeusz Pienkowski,Miguel Martin,Michael F. Press,John R. Mackey,John A. Glaspy,Arlene Chan,M. Pawlicki,Tamás Pintér,Vicente Valero,Mei Ching Liu,Guido Sauter,Gunter von Minckwitz,Frances M. Visco,Valerie Bee,Marc Buyse,Belguendouz Bendahmane,Isabelle Tabah-Fisch,Mary Ann Lindsay,Alessandro Riva,John Crown +22 more